Hermansen Simon K, Sørensen Mia D, Hansen Anker, Knudsen Steen, Alvarado Alvaro G, Lathia Justin D, Kristensen Bjarne W
Department of Pathology, Odense University Hospital, Odense, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
PLoS One. 2017 Nov 14;12(11):e0188090. doi: 10.1371/journal.pone.0188090. eCollection 2017.
Glioblastomas are among the most lethal cancers; however, recent advances in survival have increased the need for better prognostic markers. microRNAs (miRNAs) hold great prognostic potential being deregulated in glioblastomas and highly stable in stored tissue specimens. Moreover, miRNAs control multiple genes representing an additional level of gene regulation possibly more prognostically powerful than a single gene. The aim of the study was to identify a novel miRNA signature with the ability to separate patients into prognostic subgroups. Samples from 40 glioblastoma patients were included retrospectively; patients were comparable on all clinical aspects except overall survival enabling patients to be categorized as short-term or long-term survivors based on median survival. A miRNome screening was employed, and a prognostic profile was developed using leave-one-out cross-validation. We found that expression patterns of miRNAs; particularly the four miRNAs: hsa-miR-107_st, hsa-miR-548x_st, hsa-miR-3125_st and hsa-miR-331-3p_st could determine short- and long-term survival with a predicted accuracy of 78%. Heatmap dendrograms dichotomized glioblastomas into prognostic subgroups with a significant association to survival in univariate (HR 8.50; 95% CI 3.06-23.62; p<0.001) and multivariate analysis (HR 9.84; 95% CI 2.93-33.06; p<0.001). Similar tendency was seen in The Cancer Genome Atlas (TCGA) using a 2-miRNA signature of miR-107 and miR-331 (miR sum score), which were the only miRNAs available in TCGA. In TCGA, patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors and low miR sum score had the shortest survival. Adjusting for age and MGMT status, low miR sum score was associated with a poorer prognosis (HR 0.66; 95% CI 0.45-0.97; p = 0.033). A Kyoto Encyclopedia of Genes and Genomes analysis predicted the identified miRNAs to regulate genes involved in cell cycle regulation and survival. In conclusion, the biology of miRNAs is complex, but the identified 4-miRNA expression pattern could comprise promising biomarkers in glioblastoma stratifying patients into short- and long-term survivors.
胶质母细胞瘤是最致命的癌症之一;然而,近期生存率的提高增加了对更好的预后标志物的需求。微小RNA(miRNA)具有巨大的预后潜力,在胶质母细胞瘤中表达失调且在储存的组织标本中高度稳定。此外,miRNA控制多个基因,代表了基因调控的另一个层面,其预后能力可能比单个基因更强。本研究的目的是鉴定一种新型的miRNA特征,能够将患者分为预后亚组。回顾性纳入了40例胶质母细胞瘤患者的样本;除总生存期外,患者在所有临床方面均具有可比性,这使得能够根据中位生存期将患者分为短期或长期幸存者。采用miRNA组筛选,并使用留一法交叉验证建立预后模型。我们发现miRNA的表达模式;特别是四种miRNA:hsa-miR-107_st、hsa-miR-548x_st、hsa-miR-3125_st和hsa-miR-331-3p_st能够确定短期和长期生存,预测准确率为78%。热图树状图将胶质母细胞瘤分为预后亚组,在单因素分析(HR 8.50;95%CI 3.06 - 23.62;p<0.001)和多因素分析(HR 9.84;95%CI 2.93 - 33.06;p<0.001)中与生存有显著关联。在癌症基因组图谱(TCGA)中使用miR-107和miR-331的双miRNA特征(miR总和评分)也观察到了类似趋势,这是TCGA中仅有的miRNA。在TCGA中,O6-甲基鸟嘌呤-DNA甲基转移酶(MGMT)未甲基化肿瘤且miR总和评分低的患者生存期最短。调整年龄和MGMT状态后,低miR总和评分与较差的预后相关(HR 0.66;95%CI 0.45 - 0.97;p = 0.033)。京都基因与基因组百科全书分析预测所鉴定的miRNA可调控参与细胞周期调控和生存的基因。总之,miRNA的生物学特性复杂,但所鉴定的4-miRNA表达模式可能是胶质母细胞瘤中很有前景的生物标志物,可将患者分为短期和长期幸存者。